Alexei Martsinkovskiy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alexei Martsinkovskiy has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
- Andrew M. Lowy
Department of Surgery, Division of Surgical Oncology, Moores Cancer Center, University of California San Diego, San Diego, California, USA
13 shared publications - Hervé Tiriac
Department of Surgery, Division of Surgical Oncology, Moores Cancer Center, University of California San Diego, San Diego, California, USA
13 shared publications - Asimina S. Courelli
Division of Surgical Oncology, Department of Surgery, University of California San Diego, San Diego, CA
12 shared publications - Bharti Garg
University of California San Diego 6 La Jolla, California
12 shared publications - Evangeline S. Mose
University of California San Diego 1 La Jolla, CA
12 shared publications - Jay Patel
University of California San Diego 7 La Jolla, Ca
12 shared publications
Latest Publications
- 17 November 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
Targeting SUMOylation in Combination with Agonistic Anti-CD40 Therapy Activates Anti- Tumor Immunity to Control Pancreatic Cancer
Pancreatic ductal adenocarcinoma (PDAC) remains an aggressive, lethal form of cancer and available immunotherapies are ineffective for most patients. In this study, we investigated combining agonistic anti-CD40 (aCD40) with TAK-981 (TAK/subasumstat), a SUMOylation inhibitor with immune priming effects. We previously reported that TAK-981 increases CD40 expression on antigen-presenting cells, and thus we hypothesized that combining it with an agonistic CD40 antibody (aCD40) would enhance immune-mediated tumor control. We investigated the therapeutic effect of TAK-981 + aCD40 in vivo using three syngeneic, orthotopic mouse models of PDAC. Single-cell RNA sequencing, flow cytometry, and immunofluorescence/immunohistochemistry were used to identify immunogenic changes in the tumor microenvironment. T-cell and macrophage depletions were used to assess functional contributions of individual immune cell populations. We assessed the functional contributions of T-cells and macrophages by depleting their populations separately.TAK-981+aCD40 treatment augmented CD8+ T-cell and macrophage infiltration into the tumor, amplified IFNα and IFNγ signaling, decreased TGFβ signaling and increased MHC-I expression resulting in decreased tumor burden and improved median survival. Despite the induction of dramatic CD8+ T cell infiltration into tumors, the efficacy of combination therapy was not impacted by T cell deficiency or depletion. In contrast, depletion of phagocytic macrophages abolished the therapeutic benefit of combination therapy. Therefore, TAK-981+aCD40 combination therapy activates macrophage mediated anti-tumor immunity in the PDAC models. Our findings support further exploration of this combination in clinical trials to validate this combination as a strategy to generate meaningful macrophage-mediated anti-tumor immune responses in pancreatic cancer patients.
- 17 November 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
Targeting SUMOylation in Combination with Agonistic Anti-CD40 Therapy Activates Anti- Tumor Immunity to Control Pancreatic Cancer
Pancreatic ductal adenocarcinoma (PDAC) remains an aggressive, lethal form of cancer and available immunotherapies are ineffective for most patients. In this study, we investigated combining agonistic anti-CD40 (aCD40) with TAK-981 (TAK/subasumstat), a SUMOylation inhibitor with immune priming effects. We previously reported that TAK-981 increases CD40 expression on antigen-presenting cells, and thus we hypothesized that combining it with an agonistic CD40 antibody (aCD40) would enhance immune-mediated tumor control. We investigated the therapeutic effect of TAK-981 + aCD40 in vivo using three syngeneic, orthotopic mouse models of PDAC. Single-cell RNA sequencing, flow cytometry, and immunofluorescence/immunohistochemistry were used to identify immunogenic changes in the tumor microenvironment. T-cell and macrophage depletions were used to assess functional contributions of individual immune cell populations. We assessed the functional contributions of T-cells and macrophages by depleting their populations separately.TAK-981+aCD40 treatment augmented CD8+ T-cell and macrophage infiltration into the tumor, amplified IFNα and IFNγ signaling, decreased TGFβ signaling and increased MHC-I expression resulting in decreased tumor burden and improved median survival. Despite the induction of dramatic CD8+ T cell infiltration into tumors, the efficacy of combination therapy was not impacted by T cell deficiency or depletion. In contrast, depletion of phagocytic macrophages abolished the therapeutic benefit of combination therapy. Therefore, TAK-981+aCD40 combination therapy activates macrophage mediated anti-tumor immunity in the PDAC models. Our findings support further exploration of this combination in clinical trials to validate this combination as a strategy to generate meaningful macrophage-mediated anti-tumor immune responses in pancreatic cancer patients.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figures from MICAL2 Promotes Pancreatic Cancer Growth and Metastasis
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures from MICAL2 Promotes Pancreatic Cancer Growth and Metastasis
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Legends from MICAL2 Promotes Pancreatic Cancer Growth and Metastasis
Supplementary Figures and Tables legends.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Legends from MICAL2 Promotes Pancreatic Cancer Growth and Metastasis
Supplementary Figures and Tables legends.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S8 from MICAL2 Promotes Pancreatic Cancer Growth and Metastasis
Supplementary Table S8 from MICAL2 Promotes Pancreatic Cancer Growth and Metastasis
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S8 from MICAL2 Promotes Pancreatic Cancer Growth and Metastasis
Supplementary Table S8 from MICAL2 Promotes Pancreatic Cancer Growth and Metastasis
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-S6 from MICAL2 Promotes Pancreatic Cancer Growth and Metastasis
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-S6 from MICAL2 Promotes Pancreatic Cancer Growth and Metastasis
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7 from MICAL2 Promotes Pancreatic Cancer Growth and Metastasis
Supplementary Table S7 from MICAL2 Promotes Pancreatic Cancer Growth and Metastasis
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7 from MICAL2 Promotes Pancreatic Cancer Growth and Metastasis
Supplementary Table S7 from MICAL2 Promotes Pancreatic Cancer Growth and Metastasis
- Open Access
- 14 March 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7 from MICAL2 Promotes Pancreatic Cancer Growth and Metastasis
- 14 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7 from MICAL2 Promotes Pancreatic Cancer Growth and Metastasis
- Open Access
- 14 March 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Legends from MICAL2 Promotes Pancreatic Cancer Growth and Metastasis
Supplementary Figures and Tables legends.
- 14 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Legends from MICAL2 Promotes Pancreatic Cancer Growth and Metastasis
Supplementary Figures and Tables legends.
- Open Access
- 14 March 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S8 from MICAL2 Promotes Pancreatic Cancer Growth and Metastasis
- 14 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S8 from MICAL2 Promotes Pancreatic Cancer Growth and Metastasis
- Open Access
- 14 March 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures from MICAL2 Promotes Pancreatic Cancer Growth and Metastasis
- 14 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures from MICAL2 Promotes Pancreatic Cancer Growth and Metastasis